MedTrace Logo

Hemp Oil + User Experience Study

NCT04026672 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2020-02-10

No results posted yet for this study

Summary

Presented as an online survey, this study seeks to better understand how Thorne customers are using and experiencing the new Hemp Oil + product and how they feel it compares in the marketplace. Hemp Oil + is a combination product with a proprietary blend of hemp, clove, black pepper, hops, and rosemary extracts. People who have independently elected to purchase and use Hemp Oil + before the study starts will be invited to voluntarily participate. If they meet study requirements and give consent they will answer questions online about their experience with Hemp Oil +. Questions address general demographics and wellness, general impressions of the product, how it compares to other products, and any effect it has had on their gastrointestinal health, physical discomfort, sleep, and mood. The survey is expected to take 15-30 min of participant time. Data will be analyzed to determine whether the customer experience with Hemp Oil + is as favorable as it seems from anecdotal reports. Analysis will also be conducted to find patterns that can inform future studies, marketing, and customer education efforts.

Conditions

  • General Wellbeing
  • Gastrointestinal Health
  • Physical Discomfort
  • Sleep
  • Mood

Sponsors & Collaborators

  • Thorne HealthTech, Inc

    lead INDUSTRY

Principal Investigators

  • Jacqueline Jacques, ND · Thorne Research

  • Sheena Smith, MS · Thorne Research

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-22
Primary Completion
2020-02-04
Completion
2020-02-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04026672 on ClinicalTrials.gov